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Abstract
Prokineticins (PKs), consisting of PK1 and PK2, are a pair of newly identified regulatory peptides.
Two closely related G-protein coupled receptors, PKR1 and PKR2, mediate the signaling of PKs.
PKs/PKRs participate in the regulation of diverse biological processes, ranging from development
to adult physiology. A number of studies have indicated the involvement of PKs/PKRs in
nociception. Here we show that PK2 is a sensitizer for nociception. Intraplantar injection of
recombinant PK2 resulted in a strong and localized hyperalgesia with reduced thresholds to
nociceptive stimuli. PK2 mobilizes calcium in dissociated dorsal root ganglion (DRG) neurons. Mice
lacking the PK2 gene displayed strong reduction in nociception induced by thermal and chemical
stimuli, including capsaicin. However, PK2 mutant mice showed no difference in inflammatory
response to capsaicin. As the majority of PK2-responsive DRG neurons also expressed transient
receptor potential vanilloid (TRPV1) and exhibited sensitivity to capsaicin, TRPV1 is likely a
significant downstream molecule of PK2 signaling. Taken together, these results reveal that PK2
sensitize nociception without affecting inflammation.
Background
Prokineticins (PKs), consisting of PK1 and PK2, are a
novel family of regulatory peptides, whose mature forms
consist of 86 and 81 amino acids, respectively [1]. Both
PK1 and PK2 possess ten conserved cysteines and have
about 45% identity in the amino acid sequences [2]. Two
endogenous G-protein coupled receptors for PKs, PKR1
and PKR2, have been identified in humans, rats and mice
[3-5]. PKR1 and PKR2 are highly similar to each other and
appear to signal mainly through Gq pathway [3].
Several regulatory functions ranging from development to
adult physiology have been described for PKs [1,6-9]. A
number of studies have indicated the involvement of the
PKs/PKRs system in nociception. Intraplantar injection of
Bv8, the frog homolog of PKs, causes a strong and local-
ized hyperalgesia by reducing the nociceptive thresholds
to thermal and mechanical stimuli [10,11]. The hyperal-
gesia caused by Bv8 is likely due to the sensitization of
transient receptor potential vanilloid 1 (TRPV1) in dorsal
root ganglion (DRG) neurons [12]. Although both PKR1
and PKR2 are expressed in the DRG neurons, a recent
report that mice lacking the PKR1 gene exhibit impaired
pain perception to various stimuli including noxious heat,
mechanical, capsaicin, and protons implies that PKR1 is
likely to be the dominant receptor that exerts a tonic acti-
vation of TRPV1 [13].
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Whether PK1 or PK2 is responsible for the activation of
PKR1 in pain sensitization is unknown. PK2 is highly
expressed in peripheral blood cells, notably in monocytes,
neutrophils, and dendritic cells. PK2 has been identified
as a chemoattractant for monocyte/macrophage [9,14]. At
the sites of inflammation, neutrophils may release PK2
that can subsequently induce the release of proinflamma-
tory cytokines like interleukin-1 and interleukin-12 from
macrophage or other cells [15]. In contrast, PK1 was not
found in the peripheral blood cells [9]. Thus, even though
PK1 activates PKR1 with similar potency in vitro as PK2
[3], PK2 might be the dominant ligand involved in nocic-
eption, especially in inflammatory pain. In the present
study, we explored the involvement of PK2 in pain sensa-
tion. Our studies reveal that PK2 is a sensitizer for inflam-
matory pain without affecting inflammation.
Results
Nociceptive sensitization to thermal stimuli by 
intraplantar injection of PK2
It has been reported that intraplantar injection of frog Bv8
sensitized the nociceptive response to thermal stimuli in
rats [11]. We examined effect of recombinant human PK2
on nociception to thermal stimuli. When 2.5 pmole PK2
was injected into hindpaw, the withdrawal latency of the
injected hindpaw to radiant heat decreased to 40.2 ± 5.2%
of the basal value and 37.9 ± 10.3% of the contralateral
hindpaw. No change of the withdrawal latency was
observed when vehicle was injected (Fig. 1). This study
reveals that intraplantar injection of PK2 caused a strong
and localized hyperalgesia.
Mobilization of calcium in DRG neurons by PK2
PK2 is known to mobilize intracellular calcium in cells
that express PKRs exogenously [3,4]. We therefore exam-
ined the effects of PK2 on [Ca2+]i in rat DRG neurons.
Heat hyperalgesia induced by intraplantar injection of PK2 Figure 1
Heat hyperalgesia induced by intraplantar injection of PK2. Paw withdrawal latency after intraplantar injection of PK2 (2.5 
pmole) or saline were expressed as percent change from pretreatment values. PK2 significantly decreased the withdraw 
latency radiant heat. Two asterisks P < 0.01 versus saline treatment.Molecular Pain 2006, 2:35 http://www.molecularpain.com/content/2/1/35
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When 300 nM PK2 was applied, [Ca2+]i increased in about
65% of acutely dissociated DRG neurons (38/59). Fur-
thermore, 22 of the 38 (58%) PK2-responsive DRG neu-
rons exhibited sensitivity to capsaicin (Fig. 2). These
results demonstrated the partial overlapping of DRG neu-
rons that respond to PK2 and capsaicin.
Co-localization of PKRs with TRPV1 in DRG
In situ hybridization with DIG-labeled riboprobe against
PKR1 revealed its expression in many small DRG cells,
likely neurons that are involved in nociception. Many of
the PKR1-expressing cells also expressed TRPV1 (Fig. 3A–
C), although cells that expressed either PKR1 and TRPV1
were also evident. In contrast, only a small number of
DRG cells expressed PKR2 (Fig. 3D). Some of the PKR2-
postive cells also co-localized with TRPV1, whereas others
were not (Fig. 3E–F). These results were consistent with
results of calcium mobilization experiments. Interest-
ingly, we also observed the expression of PK2 mRNA in
some small DRG cells, some of which were TRPV1-posi-
tive (Fig. 3G–I). This result suggested that PK2 might be
released from terminals of DRG neurons.
Attenuated thermal nociception in PK2-/- mice
To assess the sensitivity of PK2-/- mice to noxious thermal
stimuli, we performed the tail and paw immersion tests.
The withdrawal latency of the PK2-/- mice was compara-
ble to that of wild type (WT) controls when the tail or
hindpaw was immersed into 51°C hot water. However,
PK2-/- mice exhibited significantly increased withdrawal
latencies than WT controls at 46°C and 48°C (Fig. 4A–B).
PK2-/- mice also showed longer withdrawal latencies in
cold water (4°C) tail withdrawal test (Fig. 4A). These data
indicated that the PK2-/- mice had attenuated responses to
both hot and cold thermal nociceptive stimuli.
Impaired nociceptive responses to noxious chemical 
stimuli in PK2-/- mice
Several nociceptive assays were carried out to investigate
the behavioral responses to noxious chemical stimuli in
PK2-/- mice. Capsaicin is an intensely noxious chemical
stimulus that, when injected intraplantarly into the hind-
paw, directly activates C-fibers. Intraplantar injection of
capsaicin elicited a robust shaking, licking and biting of
the hindpaw in WT animals. As shown in Fig. 5A, the noci-
Mobilization of intracellular calcium in dissociated dorsal root ganglion neurons by PK2 Figure 2
Mobilization of intracellular calcium in dissociated dorsal root ganglion neurons by PK2. The upper panel illustrates examples of 
responses of individual neurons to recombinant human PK2 (300 nM), capsaicin (1000 nM) and KCl (50 mM). The lower panel 
shows the distribution of PK2 and/or capsaicin-responsive cells in examined DRG neuronsMolecular Pain 2006, 2:35 http://www.molecularpain.com/content/2/1/35
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ceptive response to capsaicin was significantly reduced in
PK2-/- mice. In contrast, PK2+/- mice exhibited similar
response to capsaicin as WT controls. No difference was
observed among three groups of animals when the vehi-
cles were used (data no shown).
Subcutaneous injection of 5% formalin into the ventral
hindpaw elicited a biphasic behavioral response, which
can be divided into a brief early phase (0–10 min) and a
prolonged late phase (10–60 min). While no difference in
the early-phase responses was observed between PK2-/-
Co-localization of TRPV1 with PKR1, PKR2, and PK2 mRNA in DRG neurons Figure 3
Co-localization of TRPV1 with PKR1, PKR2, and PK2 mRNA in DRG neurons. TRPV1 was revealed by immunostaining (red). 
PKR1, PKR2 and PK2 expressions were revealed by in situ hybridization (green). Arrowhead ( ) showed cells co-express 
TRPV1 and PKR1, PKR2 or PK2; arrow (→) indicated cells only express TRPV1; and arrowhead ( ) revealed cells only 
express PKR1 or PKR2 or PK2. Scale bar = 25 μm.
f 
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mice and WT controls, PK2-/- mice exhibited significantly
reduced late-phase responses to subcutaneous administra-
tion of formalin (Fig. 5B–C).
We then examined the nociceptive responses of the ani-
mals to visceral pain induced by intraperitoneal adminis-
tration of acetic acid or MgSO4 solution. In both cases,
PK2-/- mice exhibited significantly attenuated abdominal
stretching response than WT controls, while the PK2+/-
mice did not differ from WT (Fig. 5D–E). Taken together,
all these behavioral experiments showed that the nocicep-
tive responses to noxious chemical stimuli were signifi-
cantly reduced in PK2-/- mice.
Intact inflammatory response to intraplantar injection of 
capsaicin in PK2-/- mice
Intraplantar injection of capsaicin induces a marked neu-
rogenic inflammation characterized by increased paw
diameter, plasma extravasation and pain [16]. As PK2
mRNA is expressed in inflammatory cells, the capsaicin-
induced inflammatory response was examined to deter-
mine whether the altered behavioral response to capsaicin
in PK2-/- mice was related to the difference in inflamma-
tory response. Fig. 6A shows that capsaicin-induced
plasma extravasation of Evans blue dye was similar in
PK2-/- and WT mice. Moreover, comparable increase of
paw diameter was also observed in PK2-/- and WT mice in
response to capsaicin injection (Fig. 6B). These results
indicated that the inflammatory response induced by cap-
saicin was intact in PK2-/- mice, even though the pain sen-
sation was attenuated.
Discussion
In this study, we investigated the role of PK2 in nocicep-
tion, particularly the inflammatory pain. One striking
phenotype of PK2-/- mice is the strong reduction in noci-
ception induced by intraplantar injections of capsaicin.
This is consistent with the observation that peripheral
injection of PK2 and frog Bv8 resulted in potentiation of
capsaicin-evoked pain behavior [12]. Intraplantar injec-
tion of capsaicin produces nociceptive behaviors in rats
and mice with a short-lasting inflammatory response
characterized by redness, swelling and plasma extravasa-
tion [16]. As PK2 is also expressed in inflammatory cells
[9,14], it was intriguing to find out whether the attenuated
nociceptive response to capsaicin in PK2-/- mice was due
to altered inflammation. No difference in inflammatory
response to capsaicin, as indicated by Evans blue dye
extravasation and equivalent paw edema, was observed
between PK2-/- and WT mice. Thus, lack of the PK2 gene
reduced the capsaicin-evoked pain sensation without
affecting inflammatory response.
Two receptors for PK2, PKR1 and PKR2, are expressed in
some DRG neurons, implying that PK2 may directly acti-
vate these PKRs-expressing neurons. Indeed, we observed
that PK2 could induce calcium mobilization in isolated
DRG neurons. Interestingly, the majority of PK2-respon-
sive DRG neurons were also sensitive to capsaicin, and the
percentage of these neurons matches the percentage
reduction of capsaicin-induced pain response in the PK2-
/- mice. Together, these suggest that activation of these
PK2-responsive, capsaicin-sensitive neurons may underlie
Nociceptive responses of WT and PK2-/- mice to thermal stimuli Figure 4
Nociceptive responses of WT and PK2-/- mice to thermal stimuli. A, Tail-withdrawal latency from hot and cold water in WT 
(black bars, n = 9) and PK2-/- mice (white bars, n = 8). PK2-/- mice exhibited significantly increased tail withdrawal latencies than 
WT controls at 46°C, 48°C and 4°C. B, Paw-withdrawal latency from hot water. PK2-/- mice exhibited significantly increased 
paw withdrawal latencies than WT controls at 46°C and 48°C. Asterisk, P < 0.05; two asterisks P < 0.01.Molecular Pain 2006, 2:35 http://www.molecularpain.com/content/2/1/35
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Nociceptive responses of WT and PK2-/- mice to noxious chemical stimuli Figure 5
Nociceptive responses of WT and PK2-/- mice to noxious chemical stimuli. A. Nociceptive responses to capsaicin. Duration of 
licking in response to intraplantar injection of capsaicin (3 μg/10 μL) in WT (black bars, n = 8), PK2+/- (grey bars, n = 7) and 
PK2-/- mice (white bars, n = 8). B. Nociceptive responses to formalin. Time course of pain behavior induced by intraplantar 
injection of 5% formalin (20 μL) in WT (filled circles, n = 9) and PK2-/- mice (open triangles, n = 8). C. Formalin-induced pain 
behavior during the early and late phases. D. Visceral pain responses to acetic acid. Abdominal stretching produced by intra-
peritoneal injection of 0.6% acetic acid (5 μl/g body weight) was recorded. E. Visceral pain response to MgSO4. Abdominal 
stretching produced by intraperitoneal injection of 0.1 mM Mg SO4 (10 μl/g body weight) was recorded. All data are mean ± 
SEM. Asterisk, P < 0.05; two asterisks P < 0.01.Molecular Pain 2006, 2:35 http://www.molecularpain.com/content/2/1/35
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the PK2-induced hypersensitivity. This is supported by
our findings that PKRs colocalize with capsaicin-gated ion
channel, TRPV1. TRPV1 can be sensitized by phosphoryla-
tion through PKC, PKA and Ca2+/CaM-dependent kinsase
II [17-20]. At sites of tissue injury or inflammation,
endogenous factors like bradykinin, prostaglandin and
ATP are released and potentiate the TRPV1 mediated noci-
ceptive response through activation of their cognate G
protein-coupled receptors [21-24]. Since PKR1 and PKR2,
two G-protein coupled receptors, co-express with TRPV1
in the DRG neurons, it is very likely that PK2 would also
sensitize TRPV1 by activating PKRs. Patch-clamp experi-
ments revealed that activation of PKRs could potentiate
TRPV1 mediated inward current in rat DRG neurons [12].
Our expression results also reveal that PKR1 is the domi-
nant receptor expressed in primary nociceptive DRG neu-
rons, consistent with the genetic study that mice lacking
the PKR1 gene showed impaired response to capsaicin
[13].
Intriguingly, where does the PK2 come from at the site of
tissue injury? Recently it has been demonstrated that PK2
is expressed in inflammatory cells and PK2 expression is
strongly increased in inflammatory paw skin of mice
[9,14]. Particularly, PK2 may be released by neutrophils,
macrophages at sites of inflammation [15]. In this study,
we showed that PK2 was also expressed in many DRG
neurons. Thus, it is probably that PK2 can be released
from the terminals of the primary sensory neurons, just
like substance P, in neurogenic inflammation.
The TRPV1 channel is known to be a critical molecular
transducer of heat and is modulated by protons [19]. In
the present study, thermal hyperalgesia was induced by
intraplantar injections of PK2. Additionally, mice lacking
the PK2 gene showed impaired thermal nociception to
noxious temperature range from 46 to 48°C, the operat-
ing range of C-polymodal nociceptors and TRPV1 [17,25].
These results indicated that PK2 likely acts through a path-
way involving TRPV1 function in vivo. As there also exist
PK2-responsive neurons that are not TRPV1-positive,
TRPV1-independent role of PK2 in pain sensation is also
likely. Interestingly, PK2-/-  mice showed attenuated
responses to noxious cold. TRPA1, another member of the
transient receptor potential (TRP) family of ion channels,
is activated by cold (~6°C) and noxious chemicals such as
mustard oil [26,27]. Thus, it is possible that PK2 may acti-
vate primary sensory neurons via TRPA1. It should also be
noted that we have previously shown that PK2 increases
the excitability of CNS neurons that express PKR2 via
modulating potassium channels [28]. Thus, PK2 may acti-
vate primary sensory neurons that express PKR1 and/or
PKR2 via different signaling pathways.
Mice lacking the PK2 gene exhibited impaired formalin-
induced imflammatory pain response. The intact early-
phase response in PK2 mutant mice suggested that the
chemonociceptor terminals mediating the acute phase are
intact in the mutant mice.  Central sensitization at the
level of spinal cord is thought to be critical for formalin-
induced persistent inflammatory pain [29-31]. The
reduced late-phase response in PK2-/- mice suggested that
PK2 might contribute to the underlying changes in central
sensitization. Thus, a reasonable explanation for the
reduced late-phase response in PK2-/- mice could be that,
PK2 is released from the central afferent terminals of pri-
mary sensory neurons after formalin injection, and, cause
central sensitization by activating PKRs in the dorsal horn
Inflammatory responses of WT and PK2-/- mice to intraplantar injection of capsaicin Figure 6
Inflammatory responses of WT and PK2-/- mice to intraplantar injection of capsaicin. A. Quantification of Evans blue extravasa-
tion 30 min after injection of capsaicin (3 μg/10 μl) or vehicle. B. Percentage of diameter increase of capsaicin injected paws 
compared to vehicle-injected paws. All data shown are mean ± SEM.Molecular Pain 2006, 2:35 http://www.molecularpain.com/content/2/1/35
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of spinal cord. This is supported by other findings indi-
cated that intrathecal injection of Bv8 could induce hyper-
algesia [11]. Clearly, much remains to be explored for the
mechanism of PK2 in pain sensitization.
In conclusion, we have found that PK2 is involved in
acute and inflammatory pain. PK2 may modulate sensiti-
zation of nociception in the peripheral and central pri-
mary sensory afferents during inflammatory pain
processing without affecting the inflammation states.
Materials and methods
Animals
Homozygous (PK2-/-), heterozygous (PK2+/-) and wild
type littermates (WT) on a C57BL/6J: 129/Ola back-
ground were generated as described [32]. All mice were 11
to 20 weeks old and weighed 22–28 g. All procedures
regarding the care and use of animals were in accordance
with institutional guidelines.
Behavioral assays
Behavioral studies were performed as described [33]. All
animals were acclimated for 60 min in individual plex-
iglass chambers prior to behavioral experiments.
Thermal nociception
For paw-withdrawal to radiant heat tests, mice were
placed on the glass surface with 30°C temperature. A
mobile radiant heat source located under the glass was
focused onto the hindpaw. The paw withdrawal latency
was recorded as baseline nociceptive threshold. The effect
of the PK2 was calculated as the percentage change relative
to baseline threshold. For Tail and paw immersion tests,
mice were gently restrained by hand, and the distal half of
the tail or one hindpaw was immersed into a water bath.
The latency to withdraw the tail or hindpaw was recorded.
The test was repeated three times with 1 hr intertrial inter-
vals at each temperature.
Chemical nociception
For capsaicin test, capsaicin, 3 μg in 10 μl (Sigma; dis-
solved in 5% ethanol, 5% Tween-80 and 90% saline), was
injected into the dorsal part of the right hindpaw using a
30G needle, after which the animals were placed on a
30°C glass surface and the time spent licking or biting the
injecting paw was recorded as the nociceptive score for 10
min after injection. Paw diameter was measured with
spring-loaded calipers. For the formalin test, mice
received a 10 μl intraplantar injection of 5% formalin and
the duration of paw licking or biting was recorded for each
5 min interval during the early phase (0–10 min) and the
late phase (10–60 min). For visceral pain, either dilute
acetic acid (5 μl/g body weight of 0.6% acetic acid solu-
tion) or MgSO4 (10 μl/g body weight of 0.1 mM MgSO4
solution) was injected into peritoneum, and the number
of abdominal stretching were measured for 20 min after
acetic acid injection or for 10 min after MgSO4 injection.
Neurogenic plasma extravasation
Neurogenic plasma extravasation was performed as
described [13]. Briefly, mice were anaesthetized and
injected intravenously with Evans blue (50 mg/kg) into
the tail vein. Five minutes later, capsaicin (3 μg/10 μl) was
injected into one paw of the animal and vehicle (5% eth-
anol, 5% Tween 80, and 90% saline) was injected into the
other paw. After 30 min the plantar skin of the paw was
removed, dried of excess liquid, weighed and incubated in
formamide for 24 h at 56°C. Extravasated Evans blue was
measured by spectrophotometer at 620 nm.
Intracellular calcium imaging
Intracellular calcium imaging of DRG neurons was per-
formed as described [34]. Briefly, DRG neurons were
acutely dissociated, and loaded with 5 μM fluorescent
indicator Fura-2 acetoxymethylester (Fura-2/AM) for 30
min at room temperature. After incubation the neurons
were washed several times with normal bath solution
(containing in mM: NaCl 125, KCl 1.0, CaCl2 5, MgCl2 1,
glucose 8, and HEPES 20, pH adjusted to 7.4) to remove
remaining Fura-2/AM. Coverslips with attached cells were
then mounted on a recording chamber and [Ca2+]i in DRG
neurons was monitored by an Attofluor Ratio Vision Dig-
ital Fluorescence Microscopy System (Atto Instruments,
Rockville, MD). Drugs were delivered by fast perfusion
onto neurons using computer-controlled gravity-fed
multibarrel perfusion system. Fluorescence was measured
with 10 Hz alternating wavelength time scanning with
excitation wavelengths of 340 and 380 nm and an emis-
sion wavelength of 510 nm. The concentration of Ca2+
was calculated by comparing the ratio of fluorescence at
340 and 380 nm against a standard curve of known
[Ca2+]i.
In situ hybridization and immunohistochemistry
DRGs at the levels of L4 and L5 were removed from wild
type mice and fixed in 4% paraformaldehyde and then
incubated in 30% sucrose at 4°C overnight. DRGs were
then embedded in OCT, and cut at 20 μm on a cryostat.
Digoxigenin (DIG)-labeled PK2, PKR1 and PKR2 ribo-
probes and their sense control riboprobes were made
using DIG RNA labeling mix from Roche. In situ hybridi-
zation using DIG-labeled riboprobes were performed
with TSA Plus Fluorescence Kit (Perkin Elmer) as
described in the instruction manual. The sections were
then incubated with rabbit anti-TRPV1 antibodies
(Chemicon International, 1:1000) at 4°C overnight. Cy3-
labeled donkey anti-rabbit IgG (Jackson ImmunoRe-
search, 1:200) was subsequently added. Sections were
counterstained with DAPI (Vector Labs) and viewed
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